$JNJ

Forminard Elizabeth sold $4.1M of JNJ

Forminard Elizabeth (EVP, Chief Legal Officer) sold 15,918 shares of JOHNSON & JOHNSON (JNJ) at an average of $257.00 ($255.93–$257.76, $4.09M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Forminard Elizabeth
Published Aug 7, 2026, 9:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$JNJ
Neutral
medium confidence
Mentioned
$JNJ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the company’s EVP and Chief Legal Officer, including trade dates, share count, and total value.

02

Market read

Traders may note insider selling, but the disclosure does not provide new operational or financial guidance for JNJ.

03

What to watch

The filing does not disclose intent, tax context, or whether additional sales occurred around the same period; without that, price reaction should be muted.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after-hours; reflects trades dated 2026-08-06

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

Johnson & Johnson disclosed via Form 4 that EVP Chief Legal Officer Forminard Elizabeth sold 15,918 shares for about $4.09M on 2026-08-06.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures or company-specific news.

Evidence & confidence

Form 4 provides transaction details but does not indicate new corporate guidance, litigation, or operational changes. The sale size is moderate relative to JNJ and lacks a stated catalyst in the filing.

Market effects

Insider selling in a mega-cap healthcare name is not a reliable sector signal without broader pattern or sector-specific regulatory/earnings catalysts.

No clear regional spillover; this is company-specific insider transaction disclosure.

Minimal global relevance; JNJ is widely held, but this filing alone does not change global fundamentals.

Counterpoint

The absence of a stated 10b5-1 plan could be misread as bearish; executives may sell for diversification or tax reasons unrelated to outlook.

Key entities

  • Johnson & Johnson

    Subject of the Form 4 insider transaction disclosure.

  • Forminard Elizabeth

    EVP, Chief Legal Officer who sold shares via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

J&J Gains as AbbVie Posts 74% Myeloma Response

J&J shares rose 1% to $277.955. AbbVie's experimental myeloma drug showed 74% response rate, 60% risk reduction. J&J's Carvykti drove 6.8% operational growth in Q2. Reuters notes AbbVie's drug complements, not replaces, J&J's treatment. J&J's stock is 44.08% above GF Value estimate.

$JNJMed

U.S. FDA warning prompts Taiwan red alert over heart pump device

Taiwan's FDA issued a red alert over a heart pump device after the U.S. FDA warned of a defect in Abiomed Inc.'s Automated Impella Controllers, linked to 3 deaths and 37 injuries. The device, used in 19 Taiwanese hospitals, is being recalled for a cartridge recognition issue. Johnson & Johnson MedTech, the local license holder, must notify providers and implement fixes.

$JNJHighAI 8/10

Johnson & Johnson cuts 2026, 2027 adjusted EPS guidance by up to $1.36

Johnson & Johnson revised its 2026 and 2027 adjusted EPS guidance downward, citing expected decreases in operational and adjusted metrics. For 2026, EPS is expected to decrease by $0.64, and for 2027, by $1.36. The company also announced a $5.5 billion settlement for talc-related claims, with the first payment of up to $3 billion due in 2027.

$JNJMedAI 8/10

Johnson & Johnson names Tom Cavanaugh as Innovative Medicine chairman

Johnson & Johnson (JNJ) appointed Tom Cavanaugh as Executive Vice President and Worldwide Chairman of its Innovative Medicine division, effective September 1, 2026. Cavanaugh succeeds Jennifer Taubert, who is retiring after 21 years. The division generated over $60 billion in annual revenue under Taubert's leadership. JNJ's shares rose 0.86% to $258.03 on Friday following two biotech acquisitions: a $1 billion cash deal for Firefly Bio and a $2.58 billion option to acquire Sail Biomedicines, whi